Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Circulating tumour DNA may be able to identify metastatic colorectal cancer patients who are likely to benefit from EGFR-targeted therapy after initial disease resistance

The COSMIC-311 trial findings add support for the use of cabozantinib in patients with differentiated thyroid cancer refractory to radioiodine and VEGFR-targeted multikinase inhibitors

The use of adjuvant chemotherapy after cisplatin-based chemoradiotherapy does not improve survival from locally advanced cervical cancer

Phase III data suggest that disease-free survival is significantly improved in patients with high-risk renal cell carcinoma who receive adjuvant pembrolizumab following nephrectomy

Adding the PD-1 inhibitor toripalimab to first-line cisplatin and gemcitabine chemotherapy improves progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma

A 12-week de-escalated neoadjuvant regimen has achieved high survival rates for HER2-positive, HR-negative early breast cancer patients

Basket trial results indicate that pertuzumab plus trastuzumab may be effective in a range of HER2-positive cancers without KRAS mutations

Phase II trial results point to the benefit of pembrolizumab in patients with BCG-unresponsive carcinoma in situ, with or without papillary tumours, who are ineligible for or decline surgery